Probity Advisors Inc. Purchases 377 Shares of Moderna, Inc. $MRNA

Probity Advisors Inc. raised its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.6% during the second quarter, HoldingsChannel.com reports. The fund owned 14,892 shares of the company’s stock after buying an additional 377 shares during the quarter. Probity Advisors Inc.’s holdings in Moderna were worth $411,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in Moderna by 1.8% during the first quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company’s stock valued at $54,382,000 after acquiring an additional 34,034 shares during the last quarter. Wealthfront Advisers LLC boosted its position in Moderna by 143.3% during the first quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company’s stock valued at $879,000 after acquiring an additional 18,268 shares during the last quarter. FORA Capital LLC boosted its position in Moderna by 31.7% during the first quarter. FORA Capital LLC now owns 97,072 shares of the company’s stock valued at $2,752,000 after acquiring an additional 23,344 shares during the last quarter. Jump Financial LLC boosted its position in Moderna by 5,590.0% during the first quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock valued at $25,584,000 after acquiring an additional 886,567 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Moderna by 12.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock valued at $74,557,000 after acquiring an additional 285,662 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 0.9%

Shares of NASDAQ MRNA opened at $27.49 on Wednesday. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $57.69. The firm has a market capitalization of $10.74 billion, a P/E ratio of -3.65 and a beta of 2.01. The firm’s 50-day moving average price is $25.98 and its 200-day moving average price is $27.12.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. During the same quarter in the prior year, the business posted ($3.33) EPS. The firm’s revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. Equities research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on MRNA shares. Barclays cut their price target on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a research report on Monday, August 4th. JPMorgan Chase & Co. set a $26.00 price objective on shares of Moderna in a report on Friday, August 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. Morgan Stanley upped their price objective on shares of Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a report on Friday, October 10th. Finally, Citigroup started coverage on shares of Moderna in a report on Friday, August 1st. They set a “neutral” rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $39.93.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.